A Phase I Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14c]-Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors
Investigational New Drugs - Netherlands
doi 10.1007/s10637-017-0509-1
Full Text
Open PDFAbstract
Available in full text
Date
September 21, 2017
Authors
Publisher
Springer Science and Business Media LLC